ArticleArchives of medical science : AMS2011
Biomarker to distinguish hepatocellular carcinoma from cholangiocarcinoma by serum a disintegrin and metalloprotease 12.
Article in Archives of medical science : AMS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Pooled it
- ADAM12 in a stromal-checkpoint framework: integrating tumor microenvironment remodeling and therapy resistance in solid tumors.Cell communication and signaling : CCS · 2026Review
- ADAM-Mediated Signalling Pathways in Gastrointestinal Cancer Formation.International journal of molecular sciences · 2020Review
- Suppression of human hepatocellular cancer cell proliferation by Brucea javanica oil-loaded liposomes via induction of apoptosis.Archives of medical science : AMS · 2015Article
- Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods.European journal of medical research · 2013Article
- Clinical application of percutaneous drainage in treating hepatocellular carcinoma with bile duct tumor thrombus.Contemporary oncology (Poznan, Poland) · 2013Article
- Predictors for the development of cholangiocarcinoma and hepatocellular carcinoma: in search for the most accurate biomarker.Archives of medical science : AMS · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe "a distintegrin and metalloprotease" (ADAM) family contributes to regulation of the cell-cell and cell-matrix interaction that are critical determinants of malignancy. It also plays important roles in the degradation of the basement membrane during tumor invasion. To evaluate a distinguishing biomarker for hepatocellular carcinoma from cholangiocarcinoma, a disintegrin and metalloprotease 12 (ADAM12) level was determined. MATERIAL AND
methodsThe indirect ELISA and Western blot analysis for quantification of ADAM12 level in serum was developed. The subjects were 218 histologically confirmed cases, 128 with intrahepatic cholangiocarcinoma, 30 with hepatocellular carcinoma and 60 healthy people.
resultsThe ability of test was verified using an analysis of Receiver Operating Characteristic (ROC) curve. The mean value of serum ADAM 12 in hepatocellular carcinoma was significantly higher than cholangiocarcinoma and healthy people (p = 0.001). The AUC for control vs. HCC was 0.826 while for controls vs. CC was 0.679. The results showed that a disintegrin and metalloprotease 12 for hepatocellular carcinoma had better specificity (77.4%) than for cholangiocarcinoma (64.5%). The serum a disintegrin and metalloprotease 12 level was also found to inversely correlate with overall survival (p = 0.02).
conclusionsA disintegrin and metalloprotease 12 would be most useful as an adjunct biomarker for distinguishing hepatocellular carcinoma from cholangiocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.